Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study

Table 1 Summary statistics table of the study group of 251 inflammatory bowel disease patients

n = 251	Median; IQR, n (%)
Age	39; 30.0-52.75
Female gender	129 (51.4)
Body mass index	24.298; 21.19-27.34
Crohn's disease	154 (61.4)
Ulcerative colitis	97 (38.6)
Inflammatory bowel disease duration (yr)	8 (5-13
Primary sclerosign cholangitis	2 (0.8)
Prior intestinal resection	73 (29.4)
Short IBDQ questionaire score	58 (50-64)
Fecal calprotectin on study entry (mg/g)	83.195 (23.45-331.8)
C-reactive protein on study entry (mg/L)	5 (2.4-8.2)
Inflammatory bowel disease therapy on entry
Mesalamine	173 (69.5)
Antibiotics	17 (6.9)
No immunosupression	66 (26.3)
Steroids	42 (16.9)
Azathioprine solo	47 (18.7)
anti TNF therapy (all)	138 (55)
anti TNF therapy solo	74 (29.5)
Infliximab solo	41 (16.3)
Adalimumab solo	33 (13.1)
Combination therapy (anti-TNF and azathioprine)	64 (25.5)
Days between 1st and 5th AT sampling	382 (353-439.8)
Liver steatosis on ultrasound (n = 155)	34 (21.9)